alx oncology (previously alexo therapeutics) is a clinical-stage immuno-oncology company developing therapies that block the cd47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. our lead candidate, alx148, is a fusion protein that comprises an engineered high affinity cd47 binding domain of sirpa linked to an inactive fc region of human immunoglobulin. alx148 is currently being investigated in a phase 1 study in combination with checkpoint inhibitors and targeted anti-cancer antibodies (nct03013218). for more information about the company, please visit our website at www.alxoncology.com
Company profile
Ticker
ALXO
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
ALX Oncology Limited • ALX Oncology Incorporated • Alexo International Holdings Limited ...
IRS number
850642577
ALXO stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7 Mar 24
8-K
Entry into a Material Definitive Agreement
26 Dec 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 23
8-K
ALX Oncology Announces Pricing of Public Offering
6 Oct 23
424B5
Prospectus supplement for primary offering
6 Oct 23
8-K
Results of Operations and Financial Condition
4 Oct 23
424B5
Prospectus supplement for primary offering
4 Oct 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 19.65 mm | 19.65 mm | 19.65 mm | 19.65 mm | 19.65 mm | 19.65 mm |
Cash burn (monthly) | 6.15 mm | 2.46 mm | 17.76 mm | 12.87 mm | 10.39 mm | 9.28 mm |
Cash used (since last report) | 36.67 mm | 14.64 mm | 105.85 mm | 76.73 mm | 61.91 mm | 55.31 mm |
Cash remaining | -17.02 mm | 5.01 mm | -86.20 mm | -57.08 mm | -42.26 mm | -35.66 mm |
Runway (months of cash) | -2.8 | 2.0 | -4.9 | -4.4 | -4.1 | -3.8 |
Institutional ownership, Q2 2023
92.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 77 |
Opened positions | 11 |
Closed positions | 22 |
Increased positions | 25 |
Reduced positions | 18 |
13F shares | Current |
---|---|
Total value | 251.94 bn |
Total shares | 46.17 mm |
Total puts | 11.50 k |
Total calls | 91.40 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
venBio Partners | 9.70 mm | $72.85 bn |
FMR | 6.13 mm | $46.04 bn |
venBio Global Strategic Fund II | 5.27 mm | $162.11 mm |
Vivo Capital | 4.22 mm | $31.69 bn |
Vivo Capital IX | 4.03 mm | $124.14 mm |
Orbimed Advisors | 2.87 mm | $21.56 bn |
LSV Associates | 2.58 mm | $79.30 mm |
BLK Blackrock | 1.79 mm | $13.43 bn |
Redmile | 1.28 mm | $9.64 bn |
Braidwell | 1.25 mm | $9.39 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Mar 24 | Lettmann Jason | Common Stock | Buy | Acquire P | No | No | 11.3117 | 4,400 | 49.77 k | 171,620 |
14 Feb 24 | Shelly Pinto | Common Stock | Grant | Acquire A | No | No | 0 | 15,000 | 0.00 | 93,591 |
14 Feb 24 | Shelly Pinto | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 15.84 | 35,000 | 554.40 k | 35,000 |
14 Feb 24 | Garcia Peter S | Common Stock | Grant | Acquire A | No | No | 0 | 25,000 | 0.00 | 110,348 |
14 Feb 24 | Garcia Peter S | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 15.84 | 80,000 | 1.27 mm | 80,000 |
14 Feb 24 | Sophia Randolph | Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 342,349 |
14 Feb 24 | Sophia Randolph | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 15.84 | 95,000 | 1.50 mm | 95,000 |
14 Feb 24 | Jaume Pons | Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 648,359 |
14 Feb 24 | Jaume Pons | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 15.84 | 95,000 | 1.50 mm | 95,000 |
News
HC Wainwright & Co. Maintains Buy on ALX Oncology Holdings, Raises Price Target to $20
11 Mar 24
ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer
8 Mar 24
Piper Sandler Maintains Overweight on ALX Oncology Holdings, Raises Price Target to $21
8 Mar 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
8 Mar 24
Stifel Downgrades ALX Oncology Holdings to Hold, Raises Price Target to $14
8 Mar 24